Targets › CREBBP
3 programs from 3 companies in 3 trials: 2 Phase 2, 1 Phase 1; Hematology, Metabolic and endocrine, Oncology; next expected readout Nov 2027.
Acetylates histones, giving a specific tag for transcriptional activation. Mediates acetylation of histone H3 at 'Lys-18' and 'Lys-27' (H3K18ac and H3K27ac, respectively). (UniProt, Q92793)
Open in Phaseline: the race on CREBBP, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Kiminori Kimura, MD | Pri-724 CBP/beta catenin inhibitor | CREBBP, CTNNB1 | Phase 2 | Liver Cirrhosis | Nov 2027 |
| Universitas Indonesia | Zinc, Chromium, Vitamin C, and Copper Supplementation Combination mineral and vitamin supplement: zinc enhances insulin signaling and glucose me | SLC30A1, CREBBP, SLC31A1 | Phase 2 | PreDiabetes | – |
| Pathos AI | Pocenbrodib Selective oral inhibitor of CBP/p300 bromodomain interaction with acetylated lysines on hi | CREBBP, EP300 | Phase 1 | mCRPC (Metastatic Castration-resistant Prostate Cancer) | Jun 2028 |
Liver Cirrhosis (1) PreDiabetes (1) mCRPC (Metastatic Castration-resistant Prostate Cancer) (1)
small molecule (2)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.